A5037865142- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Colorectal and Anal Carcinomas
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Nanoparticle-Based Drug Delivery
- Esophageal Cancer Research and Treatment
- Cancer Treatment and Pharmacology
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastrointestinal Tumor Research and Treatment
- Genetic factors in colorectal cancer
- Colorectal Cancer Surgical Treatments
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- 3D Printing in Biomedical Research
- Cancer Mechanisms and Therapy
- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Colorectal Cancer Screening and Detection
- Ferroptosis and cancer prognosis
- HER2/EGFR in Cancer Research
Chinese Academy of Medical Sciences & Peking Union Medical College
2016-2025
National Clinical Research
2021-2025
National Cancer Center
2024-2025
Xinxiang Medical University
2024
National Clinical Research Center for Digestive Diseases
2023
Sichuan University
2022
Peking Union Medical College Hospital
2010-2016
Cancer Hospital of Chinese Academy of Medical Sciences
2009-2015
Kinjo Gakuin University
2006
Anlotinib is a novel multi-target tyrosine kinase inhibitor that designed to primarily inhibit VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret. We aimed evaluate the safety, pharmacokinetics, antitumor activity of anlotinib in patients with advanced refractory solid tumors. (5–16 mg) was orally administered tumor once day on two schedules: (1) four consecutive weeks (4/0) or (2) 2-week on/1-week off (2/1). Pharmacokinetic sampling performed all patients. Twenty-one were further enrolled an...
Purpose: The prognosis for patients with refractory soft-tissue sarcoma (STS) is dismal. Anlotinib has previously shown antitumor activity on STS in preclinical and phase I studies.Patients Methods: Patients 18 years older, progressing after anthracycline-based chemotherapy, naïve from angiogenesis inhibitors, at least one measurable lesion according to RECIST 1.1, were enrolled. main subtypes eligible undifferentiated pleomorphic (UPS), liposarcoma (LPS), leiomyosarcoma (LMS), synovial...
Nanotechnology is an important and emerging industry with a projected annual market of around one trillion US dollars by 2011–2015. Concerns about the toxicity nanomaterials in humans, however, have recently been raised. Although studies nanoparticle focused on lung disease molecular link between exposure injury remained unclear. In this report, we show that cationic Starburst polyamidoamine dendrimer (PAMAM), class are being widely developed for clinical applications can induce acute vivo....
The prognosis of advanced or metastatic medullary thyroid carcinoma (MTC) is poor, and there are few therapeutic options. Anlotinib has previously shown promising antitumor activity on MTC in preclinical models a Phase I study. This II clinical trial was devised to confirm the anlotinib patients with MTC.Patients unresectable locally received once daily oral 12 mg, two weeks on/one week off, until disease progression, death, unacceptable toxicity, withdrawal consent for any reason. dose...
Abstract Purpose: This study aimed to investigate the biomarkers of sintilimab (anti–PD-1) plus IBI305 (a bevacizumab biosimilar) in advanced hepatocellular carcinoma (HCC), as well their safety and efficacy. Patients Methods: A total 50 patients with HCC received (200 mg) (7.5 or 15 mg/kg), treated every 3 weeks a phase Ib clinical study. We performed baseline serum cytokine analysis using bead-based multiplex immunoassay immunofluorescence on tissue specimens discover novel response...
Background Colorectal cancer (CRC) is the third most common in China, however, publicly available, descriptive information on clinical epidemiology of CRC limited. Methods Patients diagnosed with primary during 2005 through 2014 were sampled from 13 tertiary hospitals 9 provinces across China. Data related to sociodemographic characteristics, use diagnostic technology, treatment adoption, and expenditure extracted individual medical records. Results In full cohort 8465 patients, mean ± SD...
Abstract Background Treatment options for refractory metastatic colorectal cancer (mCRC) were limited. Anlotinib is a novel multitarget tyrosine kinase inhibitor. ALTER0703 study was conducted to assess efficacy and safety of anlotinib patients with mCRC. Materials Methods This multicenter, double-blinded, placebo-controlled, randomized phase III trial involving 33 hospitals in China. Patients had taken at least two lines therapies 2:1 receive oral (12 mg/day; days 1–14; 21 per cycle) or...
Abstract Purpose This study aimed to assess efficacy and safety of anlotinib as a first- or second-line treatment for advanced metastatic hepatocellular carcinoma (aHCC) identify the predictive plasma cytokines on anlotinib. Methods It was phase II clinical study. Patients with aHCC were recruited from October 2016 April 2019 divided into two cohorts according previous tyrosine kinase inhibitors (TKIs) therapy. Those without prior TKIs in Cohort 1 2, respectively. All patients took (12...
Background and Aims: We evaluated the efficacy safety of antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 in pretreated advanced biliary tract cancers (BTCs). Approach Results: In this pooled analysis two single‐center, phase Ib clinical trials (TQB2450‐Ib‐05 TQB2450‐Ib‐08 trials), 66 patients with BTCs who had progressed or declined were ineligible for first‐line chemotherapy included. With treatment achieved complete response, 12 partial response...
Abstract Background It remains unclear whether addition of docetaxel to the combination a platinum and fluoropyrimidine could provide more clinical benefits than doublet chemotherapies in perioperative treatment for locally advanced gastric/gastro-esophageal junction (LAG/GEJ) cancer Asia. In this randomized, phase 2 study, we assessed efficacy safety plus oxaliplatin S-1 (DOS) versus (SOX) LAG/GEJ adenocarcinoma patients. Methods Patients with cT3–4 N any M0 G/GEJ were randomized (1:1)...
Commonly, articular osteochondral tissue exists significant differences in physiological architecture, mechanical function, and biological microenvironment. However, the development of biomimetic scaffolds incorporating upper cartilage, middle tidemark-like, lower subchondral bone layers for precise repair remains elusive. This study proposed here a novel strategy to construct trilayered hydrogel with dual-differential microenvironment both factors. The cartilage-specific was achieved...
Neoadjuvant chemotherapy has been increasingly practiced on gastric cancer (GC), and histological evaluation to predict outcome is urgent in clinical practice. There are five classic tumor regression grading (TRG) systems, including Mandard-TRG system, the Japanese Gastric Cancer Association (JGCA)-TRG College of American Pathologists (CAP)-TRG China-TRG system Becker-TRG system.Totally, 192 patients adenocarcinoma (including esophagogastric junction) treated by neoadjuvant surgery were...
Abstract Objective Recent studies have reported increased mortality for right‐sided colon cancers; however, the results are conflicting different stage tumors. We examined differences in clinicopathology between right‐ and left‐sided cancers relationships cancer location (right‐ left‐side) 5‐year disease‐free survival (DFS) overall (OS). Methods identified patients from 2005 to 2008 with II/III who underwent surgery curative intent. explored impact of tumor on postoperative DFS OS using...
This open-label, randomized phase II trial was performed to compare the efficacy and safety of nimotuzumab plus S-1 cisplatin (NCS) versus (CS) alone in patients with untreated unresectable or metastatic gastric cancer first-line setting. Eligible participants were randomly assigned (1:1) receive either NCS CS. The treatment consisted 3-week cycles twice-daily 40 mg/m2 (on days 1–14) intravenous 30 1, 2), without weekly (200 mg/m2). primary endpoint objective response rate (ORR). second...
Abstract Objective To evaluate the efficacy and safety of regorafenib monotherapy or in combination with immune-checkpoint inhibitor while treating Chinese patients metastatic colorectal cancer (mCRC): a real-world study. Methods The data who received regorafenib-containing regimen as third later line treatment at ten hospitals from Aug 2017 to Jun 2020 were retrospectively analyzed, including dosing details, survival well adverse events. Survival analysis was further performed for...
155 Background: Metastatic colorectal cancer (mCRC) patients have poor prognoses with limited response to second-line chemotherapy. Therefore, it is urgent refine and design an optimal treatment regimen improve the rate prolong survival of mCRC. This study assessed safety efficacy trifluridine/tipiracil (TAS-102), irinotecan, bevacizumab in settings for mCRC patients. Methods: was a multicenter, single-arm, phase II trial. The who are refractory standard first-line treatment, including...
The NAPOLI 3 trial demonstrated that compared to the nab-paclitaxel and gemcitabine (GemNab) regimen, NALIRIFOX (5-fluorouracil, leucovorin, liposomal irinotecan, oxaliplatin) regimen can significantly improve patients' overall survival (OS) progression-free (PFS), safety of this is generally controllable. To ensure appropriateness chosen treatment, economic evaluation essential. Thus, from perspective American healthcare systems, we explored cost-effectiveness comparison between or GemNab...
Chiauranib is a novel orally active multi-target inhibitor that simultaneously inhibits the angiogenesis-related kinases (VEGFR2, VEGFR1, VEGFR3, PDGFRα, and c-Kit), mitosis-related kinase Aurora B, chronic inflammation-related CSF-1R. This phase I dose-escalation study was to determine maximum tolerated dose (MTD), safety, pharmacokinetics, preliminary antitumor activity of chiauranib in patients with refractory advanced solid tumor lymphoma. Eighteen were treated continuous dosing from 10...
Anlotinib is an oral small molecule inhibitor of multiple receptor tyrosine kinases (RTKs), which was approved by the National Medical Products Administration (NMPA) China in 2018 for third-line treatment non-small cell lung cancer (NSCLC). Here, first time, longitudinal pharmacometabonomics explored predicting malignant tumor patient responses to anlotinib, including metabolic phenotype variation, drug efficacy, and toxicity. A total 393 plasma samples from 16 subjects collected a phase I...